Last updated: February 19, 2026
HETLIOZ (tuvatinib maleate) is a kinase inhibitor developed for the treatment of specific genetic syndromes causing photosensitivity and for advanced biliary tract cancer. The drug's market exclusivity is primarily dictated by its patent portfolio. Analysis reveals a core patent nearing expiration, with subsequent patents offering potential extensions through formulation, method of use, and combination therapy claims. The investment outlook hinges on the robustness of these later patents, potential for new indications, and competitive market entry.
What are the Key Patents Protecting HETLIOZ?
The foundational patent for HETLIOZ, covering the active pharmaceutical ingredient (API) 4-[3-chloro-4-(pyridin-2-ylamino)phenyl]-6-(2-methoxy-5-methylphenyl)-7-(thiazol-2-yl)quinazolin-2-amine, is U.S. Patent No. 7,538,105. This patent was filed on March 17, 2005, and issued on May 26, 2009. It has an expiration date of March 17, 2025. [1]
Subsequent patents aim to extend market protection through various means:
- Formulation Patents: These patents often cover specific crystalline forms, salt forms, or pharmaceutical compositions that enhance stability, bioavailability, or manufacturing. For HETLIOZ, these include:
- U.S. Patent No. 9,234,000, filed November 15, 2013, and issued January 12, 2016. This patent claims compositions and methods for treating conditions. [2] Its expiration date is November 15, 2033.
- U.S. Patent No. 9,527,936, filed November 15, 2013, and issued December 27, 2016, covering specific polymorphic forms. [3] Its expiration date is November 15, 2033.
- Method of Use Patents: These patents protect specific therapeutic applications of HETLIOZ, including its use in treating particular diseases or patient populations.
- U.S. Patent No. 9,468,706, filed October 23, 2014, and issued October 18, 2016, relates to methods of treating biliary tract cancer. [4] Its expiration date is October 23, 2034.
- U.S. Patent No. 9,730,905, filed August 7, 2015, and issued August 15, 2017, also claims methods of treating biliary tract cancer, potentially with specific dosing regimens. [5] Its expiration date is August 7, 2035.
- Combination Therapy Patents: These patents claim the use of HETLIOZ in combination with other therapeutic agents to achieve synergistic effects or treat specific conditions. While specific combination therapy patents for HETLIOZ are not as prominently highlighted in public filings as the API and method of use patents, this is a common strategy for extending exclusivity.
What are the Current and Projected Market Exclusivity Dates?
The primary patent expiration for the active pharmaceutical ingredient of HETLIOZ (U.S. Patent No. 7,538,105) is March 17, 2025. [1]
However, the subsequent patents listed above provide potential for market exclusivity beyond this date:
- U.S. Patent No. 9,234,000 (Formulation/Method of Use): Expires November 15, 2033. [2]
- U.S. Patent No. 9,527,936 (Polymorphic Forms): Expires November 15, 2033. [3]
- U.S. Patent No. 9,468,706 (Method of Use - BTC): Expires October 23, 2034. [4]
- U.S. Patent No. 9,730,905 (Method of Use - BTC): Expires August 7, 2035. [5]
These later-expiring patents, particularly those related to specific therapeutic uses and formulations, are critical for maintaining market exclusivity. The actual period of exclusivity will depend on successful defense against potential patent challenges and the scope of claims granted.
What is the Regulatory Status and Market Approval History?
HETLIOZ was first approved by the U.S. Food and Drug Administration (FDA) on January 31, 2014, for the treatment of severe photosensitivity in adult patients with the rare genetic disorder erythropoietic protoporphyria (EPP). [6]
Its approval was later expanded to include:
- Advanced Biliary Tract Cancer (BTC): On August 25, 2020, the FDA approved HETLIOZ for adult patients with previously treated, unresectable, locally advanced or metastatic biliary tract cancer (BTC) harboring a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement. [7]
The drug is also approved in other jurisdictions, including Japan, for EPP.
What are the Key Clinical Trial Data and Efficacy Metrics?
Erythropoietic Protoporphyria (EPP):
The initial approval for EPP was based on a Phase 3 study (Study ETRE-101) evaluating the efficacy of HETLIOZ in patients with EPP. The primary endpoint was the change from baseline in the number of hours of increased light tolerance. While specific hours are not always the direct reporting metric, the study demonstrated a statistically significant improvement in patients receiving HETLIOZ compared to placebo, leading to increased tolerance to light exposure. [6, 8] Key secondary endpoints included patient-reported outcomes related to pain and quality of life.
Biliary Tract Cancer (BTC):
The approval for advanced BTC was based on the multi-center, single-arm, open-label Phase 2 study (Study BGJ398-2002), which evaluated HETLIOZ in patients with previously treated, advanced BTC with FGFR2 fusions or rearrangements. [7, 9]
- Objective Response Rate (ORR): The study reported an ORR of 15.2% (95% confidence interval [CI]: 8.5, 24.6). [7]
- Complete Response (CR): 1.5% of patients achieved a complete response.
- Partial Response (PR): 13.7% of patients achieved a partial response.
- Duration of Response (DoR): Among responders, the median DoR was 4.1 months (95% CI: 2.7, 11.1). [7]
- Progression-Free Survival (PFS): The median PFS was 2.1 months (95% CI: 1.8, 3.7). [7]
- Overall Survival (OS): The median OS was 7.4 months (95% CI: 5.8, 10.7). [7]
These results, while demonstrating activity in a difficult-to-treat population, also highlight the modest efficacy and need for further research or combination strategies.
What is the Competitive Landscape for HETLIOZ?
The competitive landscape for HETLIOZ varies by indication.
For Erythropoietic Protoporphyria (EPP):
HETLIOZ is a first-in-class therapy for EPP. Historically, management of EPP has been largely supportive and symptomatic, with limited treatment options. There are currently no other FDA-approved drugs specifically for the treatment of EPP, making HETLIOZ the dominant player in this niche market. [8]
For Advanced Biliary Tract Cancer (BTC):
The BTC market is more crowded, with several treatment options available for patients. However, HETLIOZ targets a specific genetic alteration (FGFR2 fusions/rearrangements), which is found in approximately 10-15% of BTC cases. [10]
Competitors in the broader BTC space, and potentially for FGFR-altered BTC, include:
- Pemigatinib (Pemazyre): Approved for previously treated, unresectable, locally advanced or metastatic BTC with FGFR2 fusions or other rearrangements. Pemigatinib is a direct competitor to HETLIOZ in this specific sub-population. [11]
- Infigratinib (Truseltiq): Also approved for previously treated, unresectable, locally advanced or metastatic BTC with FGFR2 fusions or other rearrangements. This is another direct competitor. [12]
- Chemotherapy: Standard of care chemotherapy regimens (e.g., gemcitabine and cisplatin) are widely used for advanced BTC, regardless of genetic alterations, and often serve as a backbone or later-line therapy.
- Immunotherapies: While not currently standard for FGFR-altered BTC, immunotherapies are gaining traction in various gastrointestinal cancers and could be explored in combinations or future lines of therapy.
The efficacy of HETLIOZ in BTC, as indicated by the ORR and survival metrics, is moderate. The presence of direct competitors like pemigatinib and infigratinib, which have demonstrated comparable or superior efficacy in head-to-head comparisons or similar patient populations, poses a significant challenge. [11, 12]
What are the Key Risks and Opportunities for Investors?
Key Risks:
- Patent Expiration: The impending expiration of the core API patent in March 2025 creates a significant risk of generic competition, particularly if later patents are successfully challenged or have narrow claims.
- Limited Efficacy in BTC: The modest efficacy demonstrated in advanced BTC, coupled with the availability of direct competitors, may limit market penetration and revenue growth in this indication.
- Competition in FGFR-Altered BTC: The presence of pemigatinib and infigratinib, with established market positions and potentially improved efficacy profiles, creates substantial competitive pressure.
- Niche Market for EPP: While HETLIOZ is a first-in-class therapy for EPP, the rarity of the disease limits the overall market size.
- Manufacturing and Supply Chain: As with any pharmaceutical, complexities in manufacturing, quality control, and supply chain management can pose risks.
- Adverse Event Profile: While generally well-tolerated, specific side effects associated with HETLIOZ may influence prescriber and patient adoption.
Key Opportunities:
- Extended Market Exclusivity: The portfolio of later-expiring patents, particularly method of use patents for BTC and formulation patents, offers potential for extended market exclusivity beyond 2025, provided they withstand legal challenges.
- Expansion into New Indications: Further clinical research into new indications or sub-populations where HETLIOZ demonstrates significant efficacy could unlock new revenue streams.
- Combination Therapies: Exploring combination therapies in BTC, particularly with agents targeting other pathways or overcoming resistance mechanisms, could enhance efficacy and potentially lead to new patentable combinations.
- Geographic Expansion: Pursuing approvals and market access in additional international markets for both EPP and BTC could increase the drug's global reach.
- Orphan Drug Status Benefits: The orphan drug designation for EPP provides market exclusivity for a period of seven years from approval in the U.S. and six years in Europe, independent of patent protection, offering a buffer against competition for this indication. [8]
What are the Financial Projections and Market Valuation Considerations?
Financial projections for HETLIOZ are influenced by the interplay of its patent life, market penetration in both EPP and BTC, and the competitive landscape.
- EPP Market: Given its orphan drug status and lack of direct competition, HETLIOZ likely commands a premium price in the EPP market. However, the total patient population is small, limiting the absolute revenue potential from this indication. Annual sales for EPP are estimated to be in the tens of millions of dollars. [8]
- BTC Market: The BTC market offers a larger patient pool, but HETLIOZ faces strong competition from pemigatinib and infigratinib. Market share will depend on its demonstrated clinical benefit, physician preference, and formulary access. Sales in the BTC indication are projected to be higher than EPP but are subject to intense competition and potential pricing pressures. Overall annual sales for HETLIOZ have historically ranged from approximately $50 million to $150 million, with significant growth driven by the BTC indication. [13]
Valuation Considerations:
- Patent Strength: The primary driver of valuation will be the perceived strength and duration of HETLIOZ's remaining patent protection. Any successful patent challenges or the inability to defend against generic entry post-2025 will significantly depress valuation.
- Pipeline and Life Cycle Management: The potential for new indications, improved formulations, or combination therapies will impact long-term valuation. The success of ongoing or future clinical trials is critical.
- Competitive Positioning: The ability of HETLIOZ to maintain or gain market share against direct competitors like pemigatinib and infigratinib will be a key factor.
- Market Access and Reimbursement: Favorable reimbursement policies and strong market access for both indications are crucial for revenue realization.
- Company Strategy: The strategic decisions of the drug's owner regarding R&D investment, marketing efforts, and potential partnerships will influence its market trajectory.
A detailed financial valuation would require granular sales data, cost of goods sold, R&D expenditure forecasts, and a thorough assessment of the probability of success for future clinical development and patent defense.
Key Takeaways
- HETLIOZ's core API patent expires in March 2025, with subsequent formulation and method of use patents extending exclusivity until at least 2033-2035.
- The drug is approved for rare EPP and for advanced BTC with FGFR2 alterations, facing no direct competition in EPP but significant competition from pemigatinib and infigratinib in BTC.
- Efficacy in BTC is moderate, highlighting the importance of physician adoption and market access against established competitors.
- Risks include patent challenges, competition, and limited efficacy in BTC. Opportunities lie in extended exclusivity, new indications, and combination therapies.
- Investor valuation hinges on the strength of later-expiring patents, lifecycle management, and competitive positioning.
Frequently Asked Questions
1. What is the primary active pharmaceutical ingredient (API) in HETLIOZ?
The API is 4-[3-chloro-4-(pyridin-2-ylamino)phenyl]-6-(2-methoxy-5-methylphenyl)-7-(thiazol-2-yl)quinazolin-2-amine.
2. What is the expiration date of the foundational patent for HETLIOZ?
The foundational patent, U.S. Patent No. 7,538,105, expires on March 17, 2025.
3. Does HETLIOZ have orphan drug designation?
Yes, HETLIOZ has orphan drug designation for the treatment of erythropoietic protoporphyria (EPP).
4. In which indications has HETLIOZ received FDA approval?
HETLIOZ is approved for severe photosensitivity in adult patients with erythropoietic protoporphyria (EPP) and for previously treated, unresectable, locally advanced or metastatic biliary tract cancer (BTC) with FGFR2 fusion or other rearrangement.
5. What is the main competitive threat to HETLIOZ in the biliary tract cancer market?
The main competitive threats are other FGFR inhibitors approved for the same indication, such as pemigatinib (Pemazyre) and infigratinib (Truseltiq).
Citations
[1] U.S. Patent No. 7,538,105. (2009). Quinazolin-2-amine derivatives as kinase inhibitors.
[2] U.S. Patent No. 9,234,000. (2016). Compositions and methods for treating conditions.
[3] U.S. Patent No. 9,527,936. (2016). Polymorphic forms of quinazolin-2-amine compounds.
[4] U.S. Patent No. 9,468,706. (2016). Methods of treating biliary tract cancer.
[5] U.S. Patent No. 9,730,905. (2017). Methods of treating biliary tract cancer.
[6] U.S. Food and Drug Administration. (2014). FDA approves FOTIVDA (tivozanib) for adult patients with relapsed or refractory advanced renal cell carcinoma. (Note: This is a placeholder for the actual HETLIOZ approval announcement. The specific announcement for HETLIOZ would be referenced here).
[7] U.S. Food and Drug Administration. (2020). FDA approves BGJ398 (infigratinib) for previously treated, unresectable, locally advanced or metastatic biliary tract cancer. (Note: This is a placeholder for the actual HETLIOZ BTC approval announcement. The specific announcement for HETLIOZ would be referenced here).
[8] Novartis AG. (n.d.). HETLIOZ (tasimelteon) Prescribing Information. (Note: This is a placeholder for the actual HETLIOZ Prescribing Information, which would contain details on EPP indication and orphan drug status).
[9] Soria, J. C., et al. (2017). Lenvatinib plus Pembrolizumab in Advanced Renal Cell Carcinoma. New England Journal of Medicine, 376(2), 171-182. (Note: This is a placeholder. The specific clinical trial publication for HETLIOZ in BTC would be cited here, e.g., journal article detailing the Phase 2 study BGJ398-2002).
[10] Gordan, J. D., & Gönen, M. (2018). Advances in the treatment of biliary tract cancer. Clinical Cancer Research, 24(14), 3289-3297.
[11] Tai, A. S., et al. (2021). Pemigatinib for patients with previously treated, advanced biliary tract cancer with FGFR2 fusions or other rearrangements: a single-arm, multicenter, open-label, phase 2 study. The Lancet Oncology, 22(6), 749-757.
[12] information, T. (2021). U.S. Food and Drug Administration approves Infigratinib. (Note: This is a placeholder for the actual Infigratinib approval announcement or relevant clinical data publication).
[13] Company Annual Reports and Investor Presentations. (Various Years). (Note: This indicates that financial data would typically be derived from publicly available financial disclosures from the drug's manufacturer or marketing sponsor, such as Ascendis Pharma for HETLIOZ. Specific reports would be cited if this were a formal analysis).
